ARDM - アラディグム (Aradigm Corporation) アラディグム

 ARDMのチャート


 ARDMの企業情報

symbol ARDM
会社名 Aradigm Corp. (アラディグム)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.  アラディグムは重症呼吸器疾患の治療薬の開発と商品化に焦点を置く米国の製薬会社。非嚢胞・嚢胞性線維症に伴う気管支拡張症の吸入剤ニュ―キノロン系抗生物質シプロフロキサシン「Pulmaquin」と「Lipoquin」の治験を行う。また、非結核性抗酸菌、急性Q熱、炭疽菌吸引に対するシプロフロキサシンリポソ―ム製剤の開発を行う。   Focuses on the development and commercialization of drugs
本社所在地 3929 Point Eden Way Hayward CA 94545 USA
代表者氏名 John M. Siebert ジョン・M・シーベルト
代表者役職名 Executive Chairman of the Board Interim Principal Executive Officer Acting Principal Financial Officer
電話番号 +1 510-265-9000
設立年月日 33239
市場名 NASDAQ Small Cap
ipoyear 1996年
従業員数 23人
url www.aradigm.com
nasdaq_url https://www.nasdaq.com/symbol/ardm
adr_tso
EBITDA EBITDA(百万ドル) -12.56600
終値(lastsale) 1.3999
時価総額(marketcap) 21280190.6778
時価総額 時価総額(百万ドル) 20.97769
売上高 売上高(百万ドル) 6.82600
企業価値(EV) 企業価値(EV)(百万ドル) 39.74769
当期純利益 当期純利益(百万ドル) -16.66600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aradigm Corporation revenues decreased 82% to $1.7M. Net loss increased from $2.6M to $8.6M. Revenues reflect Contract revenue - related party decrease of 84% to $1.4M Contract revenue decrease of 47% to $124K. Higher net loss reflects Interest expense increase of 7% to $2M (expense) Other income (expense) decrease from $8K (income) to $39K (expense).

 ARDMのテクニカル分析


 ARDMのニュース

   Aradigm advancing European marketing application for Apulmiq  2019/01/30 14:58:05 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha
   Aradigm to meet with FDA to get Apulmiq NDA back on track  2019/01/16 13:48:45 Seeking Alpha
   Aradigm advancing European marketing application for Apulmiq  2019/01/30 14:58:05 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha
   Aradigm to meet with FDA to get Apulmiq NDA back on track  2019/01/16 13:48:45 Seeking Alpha
   Aradigm advancing European marketing application for Apulmiq  2019/01/30 14:58:05 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha
   Aradigm to meet with FDA to get Apulmiq NDA back on track  2019/01/16 13:48:45 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アラディグム ARDM Aradigm Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)